Last reviewed · How we verify

Iopamidol injection 76% — Competitive Intelligence Brief

Iopamidol injection 76% (Iopamidol injection 76%) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Iodinated contrast agent. Area: Diagnostic Imaging.

marketed Iodinated contrast agent Diagnostic Imaging Small molecule Live · refreshed every 30 min

Target snapshot

Iopamidol injection 76% (Iopamidol injection 76%) — Bracco Diagnostics, Inc. Iopamidol is a non-ionic iodinated contrast agent that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Iopamidol injection 76% TARGET Iopamidol injection 76% Bracco Diagnostics, Inc marketed Iodinated contrast agent
contrast agent (iopromide) contrast agent (iopromide) Seoul National University Bundang Hospital marketed Non-ionic iodinated contrast agent
Iopamidol 300 (Contrast) Iopamidol 300 (Contrast) University of Michigan marketed Non-ionic iodinated contrast agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Iodinated contrast agent class)

  1. Bracco Diagnostics, Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Iopamidol injection 76% — Competitive Intelligence Brief. https://druglandscape.com/ci/iopamidol-injection-76. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: